PANSS and TESS were used to assess the clinic and side effects.
用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和不良反应。
Symptoms were measured with the positive and negative syndrome scale (PANSS).
采用阳性与阴性症状量表(PANSS)评定精神症状。
Psychiatric symptoms were assessed by Positive and Negative Syndrome Scale (PANSS).
并用阳性和阴性症状量表(PANSS)评定患者的精神症状。
Positive and negative symptoms scale (PANSS) were used to evaluate the severity of the symptoms.
用阳性与阴性症状量表(PANSS)于治疗前后对症状严重程度进行评定。
Mental symptoms and the severity of the disease were evaluated with positive and negative syndrome scale(PANSS).
用阳性和阴性症状量表（PANSS）评定患者的精神症状及严重程度。
Brief psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) were used to assess the effects.
采用简明精神病量表(BPRS)、阳性和阴性症状量表(PANSS)进行评价。
The efficacy was evaluated by positive and negative symptom scale(PANSS), and the side effects by treatment emergent symptom scale(TESS).
以阳性和阴性症状量表（PANSS）评定临床疗效，以副反应量表（TESS）评定不良反应。
Positive and Negative Syndrome Scale (PANSS) was used to assess the efficacy, side effects scale (TESS) was used to assess adverse reactions.
采用阳性与阴性症状量表（PANSS）评定疗效，副反应量表（TESS）评定不良反应。
Results:After 8.12 week treatment, the total scores of PANSS and negative symptom scale were significantly different between two groups(P<0.05).
结果治疗后8、12周，两组PANSS总分、阴性因子分比较差异有统计学意义（P<0.05）。
Positive and negative symptom scale (PANSS) and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and side effects respectively.
用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和不良反应。
General information and body mass index (BMI) of the patients were recorded, and the clinical symptoms were assessed with the positive and negative symptom scale (PANSS).
同时观察记录患者的一般资料、体质量指数等，并用阳性及阴性症状量表(PANSS)评定患者的临床症状。
All the patients were evaluated with the positive and negative symptoms scale (PANSS) and WHO Quality of Life Survey (WHOQOL 100) before treatment and 1 year after discharge.
于治疗前、出院1年后采用阳性和阴性症状量表(PANSS)及生活质量量表(WHOQOL - 100)进行精神症状和生活质量的评定。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效，采用不良反应量表(TESS)评定该药物的副反应。
The efficiency and side effects were assessed with the postive and negative symptom scale (PANSS)and treatment emergent symptom seale (TESS) before and 4,8and 12 weekends after the treatment.
在治疗前，治疗后4、8和12周末分别以阻性症状和阴性症状量表（PANSS）和副反应量表（TESS）评定疗效和副作用。
Methods:The executive function and insight were assessed in 63 patients suffering from schizophrenic on the Positive and Negative Syndrome Scale(PANSS), and Wisconsin Card Sorting Test(WCST).
方法：应用阴性和阳性症状量表（PANSS） ，韦氏康量卡片分类测验（WCST）对6 3例精神分裂症的自知力及执行功能进行了评定。
Results: After 1 week and 4 weeks treatment, the total scores of PANSS, scores of positive symptoms and psychopathology were significantly decreased in sodium valproate group than in controlled group.
结果：合用组治疗1周后及治疗结束时PANSS量表总分、阳性症状、精神病理症状的评分比单用组明显为低。
Results: After 1 week and 4 weeks treatment, the total scores of PANSS, scores of positive symptoms and psychopathology were significantly decreased in sodium valproate group than in controlled group.
结果：合用组治疗1周后及治疗结束时PANSS量表总分、阳性症状、精神病理症状的评分比单用组明显为低。
应用推荐